FENC Stock Analysis: Buy, Sell, or Hold?
FENC - Fennec Pharmaceuticals Inc. Common Stock
$10.75
0.26 (2.48%)
▲
5d:
+0.56%
30d:
+23.56%
90d:
+85.03%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
29d
Get Alerted When FENC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: FENC trades at premium valuation expecting 5.2% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: FENC trades at premium valuation expecting 5.2% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.02
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.19
3.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FENC is currently trading at $10.75, which is considered extended relative to its 30-day fair value range of $9.03 to $10.70. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.1) compared to its historical average (10.4). At these levels, the market is pricing in 5.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, FENC is showing sideways momentum. The price is approaching resistance at $10.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.67 (+45.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FENC is showing sideways momentum. The price is approaching resistance at $10.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $15.67 (+45.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.03 -
$10.70
Company Quality Score
61/100
(BUY)
Options IV Signal
39th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
53.8%
All Signals
- BEARISH: Price extended above range
- NEUTRAL: Options fairly priced (IV 39th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.7% below Wall St target ($15.67)
- NEUTRAL: Trading at premium valuation - market expects 5.2% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$9.03 -
$10.70
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.23
(11.4%)
Support & Resistance Levels
Support Level
$8.57
Resistance Level
$10.28
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.08
Wall Street Target
$15.67
(+45.7%)
Revenue Growth (YoY)
72.6%
Profit Margin
-16.4%
Valuation Premium vs History
+5.2% premium
PE vs Historical
12.1 vs 10.4
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.2%
(market-implied from PE analysis)
1-Year Target
$11.31
(+5%)
2-Year Target
$11.90
(+11%)
3-Year Target
$12.52
(+16%)
3-Yr Target (if PE normalizes)
(PE: 12→10)
PE COMPRESSION
$10.78
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 200.7%)
$65.42
(+509%)
Base:
(SPY PE: 12.1, Growth: 200.7%)
$36.28
(+238%)
Bear:
(PE: 10.3, Growth: 200.7%)
$30.84
(+187%)
Share & Embed Analysis
Last updated: July 14, 2026 5:08 AM ET
Data refreshes hourly during market hours. Next update: 6:08 AM
Data refreshes hourly during market hours. Next update: 6:08 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FENC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Rosty Raykov
SELL
10946 shares
2026-04-01
Rosty Raykov
SELL
10349 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
